OTCMKTS:ZYXIZynex Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Zynex Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $19.42 +0.49 (+2.59 %) (As of 05/29/2020 12:22 PM ET) Add Compare Share Today's Range$19.14Now: $19.42▼$19.9950-Day Range$11.93MA: $16.43▼$21.7452-Week Range$6.96Now: $19.42▼$22.75Volume182,188 shsAverage Volume527,129 shsMarket Capitalization$644.61 millionP/E Ratio88.27Dividend YieldN/ABeta1.05 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Zynex, Inc., a medical technology company, designs, manufactures, and markets electrotherapy medical devices used for pain management and rehabilitation. Its products include NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation device; NeuroMove, an electromyography triggered electrical stimulation device; and InWave, an electrical stimulation product for the treatment of female urinary incontinence. The company also distributes private labeled products, such as electrodes for the delivery of electrical current to the body; batteries for use in electrotherapy products; Comfortrac for cervical traction; JetStream for hot/cold therapy; and LSO Back Braces for lumbar support. In addition, it develops non-invasive blood volume monitors for use in hospitals and surgery centers. The company offers its products for pain management and control; and stroke and spinal cord injury rehabilitation. It sells its products through direct and independent sales representatives primarily in the United States. Zynex, Inc. was founded in 1996 and is headquartered in Englewood, Colorado.Read More Beat the Market (BTM) Rank™ 2.3 Analyst's Opinion Consensus RatingZynex has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $22.17, Zynex has a potential upside of 12.9% from its current price of $19.63.Amount of Analyst CoverageZynex has only been the subject of 3 research reports in the past 90 days. Previous Next 2.8 Community Rank Outperform VotesZynex has received 183 “outperform” votes. (Add your “outperform” vote.)Underperform VotesZynex has received 144 “underperform” votes. (Add your “underperform” vote.)Community SentimentZynex has received 55.96% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Zynex and other stocks. Vote “Outperform” if you believe ZYXI will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ZYXI will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldZynex does not currently pay a dividend.Dividend GrowthZynex does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Zynex insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 0.05% of the stock of Zynex is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Zynex are expected to grow by 17.86% in the coming year, from $0.28 to $0.33 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Zynex is 89.23, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 14.80.Price to Earnings Ratio vs. SectorThe P/E ratio of Zynex is 89.23, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 26.09.Price to Book Value per Share RatioZynex has a P/B Ratio of 130.87. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 2.3Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.15 out of 5 stars Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Electromedical equipment Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:ZYXI Previous Symbol CUSIPN/A CIK846475 Webwww.zynexmed.com Phone303-703-4906Debt Debt-to-Equity RatioN/A Current Ratio3.45 Quick Ratio3.23Price-To-Earnings Trailing P/E Ratio88.27 Forward P/E Ratio69.36 P/E GrowthN/A Sales & Book Value Annual Sales$23.43 million Price / Sales27.51 Cash Flow$1.08 per share Price / Cash Flow17.91 Book Value$0.15 per share Price / Book129.47Profitability EPS (Most Recent Fiscal Year)$0.22 Net Income$7.36 million Net Margins33.33% Return on Equity152.81% Return on Assets95.46%Miscellaneous EmployeesN/A Outstanding Shares33,193,000Market Cap$644.61 million Next Earnings DateN/A OptionableNot Optionable OTC:ZYXI Rates by TradingView Receive ZYXI News and Ratings via Email Sign-up to receive the latest news and ratings for ZYXI and its competitors with MarketBeat's FREE daily newsletter. Zynex (OTCMKTS:ZYXI) Frequently Asked Questions How has Zynex's stock been impacted by COVID-19 (Coronavirus)? Zynex's stock was trading at $11.09 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ZYXI shares have increased by 77.0% and is now trading at $19.63. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Zynex? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zynex in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Zynex. How were Zynex's earnings last quarter? Zynex Inc. (OTCMKTS:ZYXI) posted its earnings results on Tuesday, April, 28th. The company reported $0.09 EPS for the quarter, beating the consensus estimate of $0.07 by $0.02. The company earned $15.23 million during the quarter, compared to analyst estimates of $15.07 million. Zynex had a return on equity of 152.81% and a net margin of 33.33%. View Zynex's earnings history. What guidance has Zynex issued on next quarter's earnings? Zynex updated its second quarter 2020 After-Hours earnings guidance on Tuesday, April, 28th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $17.5-18 million, compared to the consensus revenue estimate of $16.95 million. What price target have analysts set for ZYXI? 3 brokers have issued twelve-month target prices for Zynex's shares. Their forecasts range from $20.00 to $25.50. On average, they anticipate Zynex's share price to reach $22.17 in the next year. This suggests a possible upside of 12.9% from the stock's current price. View analysts' price targets for Zynex. Has Zynex been receiving favorable news coverage? Headlines about ZYXI stock have been trending somewhat negative recently, InfoTrie Sentiment reports. The research firm rates the sentiment of media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Zynex earned a coverage optimism score of -1.0 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the stock's share price in the near future. View the latest news aboutZynex. Who are some of Zynex's key competitors? Some companies that are related to Zynex include CONMED (CNMD), InMode (INMD), Natus Medical (NTUS), AxoGen (AXGN), BioLife Solutions (BLFS), TransMedics Group (TMDX), Stereotaxis (STXS), Semler Scientific (SMLR), Viewray (VRAY), BioSig Technologies (BSGM), Cutera (CUTR), Soleno Therapeutics (SLNO), Fonar (FONR), Edap Tms (EDAP) and Fc Global Realty (FCRE). View all competitors. What other stocks do shareholders of Zynex own? Based on aggregate information from My MarketBeat watchlists, some companies that other Zynex investors own include Aurora Cannabis (ACB), FuelCell Energy (FCEL), Pfizer (PFE), AT&T (T), Exxon Mobil (XOM), Aytu Bioscience (AYTU), BioDelivery Sciences International (BDSI), Canopy Growth (CGC), IBM (IBM) and Melinta Therapeutics (MLNT). Who are Zynex's key executives? Zynex's management team includes the following people: Mr. Thomas Sandgaard, Founder, Pres, CEO & Chairman (Age 60)Mr. Daniel J. Moorhead, Chief Financial Officer (Age 47)Mr. David B. Mogill, VP of OperationsMr. Robert Bird, VP of MarketingMr. Steve Siefring, Director of Bus. Devel. What is Zynex's stock symbol? Zynex trades on the OTCMKTS under the ticker symbol "ZYXI." Who are Zynex's major shareholders? Zynex's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (2.43%), Soleus Capital Management L.P. (1.05%), State Street Corp (1.00%), Calamos Advisors LLC (0.78%), Geode Capital Management LLC (0.75%) and Russell Investments Group Ltd. (0.69%). Company insiders that own Zynex stock include Daniel J Moorhead and Thomas Sandgaard. View institutional ownership trends for Zynex. Which institutional investors are selling Zynex stock? ZYXI stock was sold by a variety of institutional investors in the last quarter, including Cadence Capital Management LLC, Nuveen Asset Management LLC, WINTON GROUP Ltd, Deutsche Bank AG, BlackRock Inc., UBS Group AG, Bank of New York Mellon Corp, and Engineers Gate Manager LP. Company insiders that have sold Zynex company stock in the last year include Daniel J Moorhead, and Thomas Sandgaard. View insider buying and selling activity for Zynex. Which institutional investors are buying Zynex stock? ZYXI stock was purchased by a variety of institutional investors in the last quarter, including Soleus Capital Management L.P., EAM Global Investors LLC, EAM Investors LLC, Advisor Group Holdings Inc., Invesco Ltd., Russell Investments Group Ltd., Redmond Asset Management LLC, and AQR Capital Management LLC. View insider buying and selling activity for Zynex. How do I buy shares of Zynex? Shares of ZYXI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Zynex's stock price today? One share of ZYXI stock can currently be purchased for approximately $19.63. How big of a company is Zynex? Zynex has a market capitalization of $651.58 million and generates $23.43 million in revenue each year. The company earns $7.36 million in net income (profit) each year or $0.22 on an earnings per share basis. What is Zynex's official website? The official website for Zynex is www.zynexmed.com. How can I contact Zynex? Zynex's mailing address is 9555 MAROON CIRCLE, ENGLEWOOD CO, 80112. The company can be reached via phone at 303-703-4906 or via email at [email protected] This page was last updated on 5/29/2020 by MarketBeat.com Staff
